Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients

Despite the efficacy of decitabine to myelodysplastic syndrome (MDS), there is a wide range of responses, and no definite predictive marker has been identified. This study aimed to describe the efficacy of decitabine and to identify potential predictors of response and survival in patients with MDS....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Jung, Hyun Ae, Maeng, Chi Hoon, Kim, Moonjin, Kim, Sungmin, Jung, Chul Won, Jang, Jun Ho
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599296/
https://ncbi.nlm.nih.gov/pubmed/25938546
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares